tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ABBV Stock Latest News

AbbVie’s Ubrogepant Study: A Potential Game-Changer for Menstrual Migraine Treatment
Company AnnouncementsAbbVie’s Ubrogepant Study: A Potential Game-Changer for Menstrual Migraine Treatment
20h ago
ABBV
AbbVie and Genmab’s Promising Phase 3 Trial for Follicular Lymphoma
PremiumCompany Announcements
AbbVie and Genmab’s Promising Phase 3 Trial for Follicular Lymphoma
20h ago
ABBV
GMAB
AbbVie and Genmab’s Promising New Study for DLBCL Treatment
PremiumCompany Announcements
AbbVie and Genmab’s Promising New Study for DLBCL Treatment
20h ago
ABBV
GMAB
AbbVie’s Promising Phase 3 Study on Atogepant for Menstrual Migraine Prevention
PremiumCompany Announcements
AbbVie’s Promising Phase 3 Study on Atogepant for Menstrual Migraine Prevention
20h ago
ABBV
AbbVie and Genmab’s Promising B-Cell Lymphoma Trial: A Potential Game-Changer?
PremiumCompany Announcements
AbbVie and Genmab’s Promising B-Cell Lymphoma Trial: A Potential Game-Changer?
20h ago
ABBV
GMAB
Pfizer and AbbVie Collaborate on Promising Pediatric Antibiotic Study
PremiumCompany AnnouncementsPfizer and AbbVie Collaborate on Promising Pediatric Antibiotic Study
20h ago
PFE
ABBV
AbbVie and Genmab’s Promising Phase 3 Study for DLBCL: What Investors Need to Know
Premium
Company Announcements
AbbVie and Genmab’s Promising Phase 3 Study for DLBCL: What Investors Need to Know
20h ago
ABBV
GMAB
AbbVie and Genmab’s Epcoritamab Trial: A Promising Update for B-Cell Lymphoma Treatment
Premium
Company Announcements
AbbVie and Genmab’s Epcoritamab Trial: A Promising Update for B-Cell Lymphoma Treatment
20h ago
ABBV
GMAB
AbbVie’s ABBV-101 Study: A Potential Game-Changer in B-Cell Malignancy Treatment
PremiumCompany Announcements
AbbVie’s ABBV-101 Study: A Potential Game-Changer in B-Cell Malignancy Treatment
20h ago
ABBV
AbbVie’s Pediatric Atopic Dermatitis Study: A Potential Game-Changer?
PremiumCompany Announcements
AbbVie’s Pediatric Atopic Dermatitis Study: A Potential Game-Changer?
20h ago
ABBV
AbbVie’s New Study on Psoriatic Arthritis: A Potential Game-Changer?
PremiumCompany Announcements
AbbVie’s New Study on Psoriatic Arthritis: A Potential Game-Changer?
20h ago
ABBV
AbbVie and Genmab’s Promising Epcoritamab Study in B-cell Non-Hodgkin Lymphoma
PremiumCompany Announcements
AbbVie and Genmab’s Promising Epcoritamab Study in B-cell Non-Hodgkin Lymphoma
20h ago
ABBV
GMAB
AbbVie’s Phase 3 Study on Lutikizumab: A Potential Game-Changer for Hidradenitis Suppurativa
PremiumCompany AnnouncementsAbbVie’s Phase 3 Study on Lutikizumab: A Potential Game-Changer for Hidradenitis Suppurativa
20h ago
ABBV
AbbVie’s Latest Study on Ulcerative Colitis: A Potential Game-Changer?
Premium
Company Announcements
AbbVie’s Latest Study on Ulcerative Colitis: A Potential Game-Changer?
20h ago
ABBV
AbbVie’s Promising Phase 2 Study on Metastatic Colorectal Cancer
Premium
Company Announcements
AbbVie’s Promising Phase 2 Study on Metastatic Colorectal Cancer
20h ago
ABBV
AbbVie’s Promising Study on Etentamig for Multiple Myeloma: A Potential Game-Changer
PremiumCompany Announcements
AbbVie’s Promising Study on Etentamig for Multiple Myeloma: A Potential Game-Changer
20h ago
ABBV
AbbVie and Genmab’s Promising NHL Study: A Closer Look
PremiumCompany Announcements
AbbVie and Genmab’s Promising NHL Study: A Closer Look
20h ago
ABBV
GMAB
AbbVie’s Bimatoprost SR Study: A Long-term Look at Glaucoma Treatment
PremiumCompany Announcements
AbbVie’s Bimatoprost SR Study: A Long-term Look at Glaucoma Treatment
20h ago
ABBV
AbbVie’s IMGN151 Study: A Promising Step in Gynecological Cancer Treatment
PremiumCompany Announcements
AbbVie’s IMGN151 Study: A Promising Step in Gynecological Cancer Treatment
20h ago
ABBV
AbbVie Advances Phase 2 Study for ADPKD Treatment with ABBV-CLS-628
PremiumCompany AnnouncementsAbbVie Advances Phase 2 Study for ADPKD Treatment with ABBV-CLS-628
20h ago
ABBV
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy
Premium
The Fly
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy
1d ago
ABBV
RGNX
AbbVie upgraded to Outperform from Neutral at Daiwa
Premium
The Fly
AbbVie upgraded to Outperform from Neutral at Daiwa
1d ago
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >